Avalo Therapeutics, Inc. (NASDAQ:AVTX) Stock Has Average Price Target of $45.10 According to Brokerages

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has been given an average recommendation of “Moderate Buy” by the thirteen ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $45.10.

Several analysts have recently weighed in on the stock. Guggenheim set a $48.00 target price on shares of Avalo Therapeutics and gave the company a “buy” rating in a report on Friday, August 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of Avalo Therapeutics in a report on Wednesday, September 16th. BTIG Research restated a “buy” rating and issued a $58.00 price objective on shares of Avalo Therapeutics in a research report on Tuesday, June 16th. Leerink Partners initiated coverage on shares of Avalo Therapeutics in a research report on Monday, July 6th. They issued an “outperform” rating and a $38.00 price objective for the company. Finally, HC Wainwright lowered their price objective on Avalo Therapeutics from $35.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, August 7th.

Avalo Therapeutics Price Performance

Shares of NASDAQ AVTX opened at $15.47 on Friday. The stock has a fifty day moving average price of $18.48 and a 200 day moving average price of $16.97. Avalo Therapeutics has a 1-year low of $10.70 and a 1-year high of $24.27. The company has a market cap of $829.66 million, a PE ratio of -3.54 and a beta of 0.78.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.25). Analysts anticipate that Avalo Therapeutics will post -2.82 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Christopher Sullivan sold 12,394 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $16.33, for a total value of $202,394.02. Following the completion of the sale, the chief financial officer directly owned 39,900 shares of the company’s stock, valued at $651,567. This trade represents a 23.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 24,258 shares of company stock worth $415,434. Corporate insiders own 4.46% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of AVTX. Braidwell LP purchased a new position in Avalo Therapeutics in the second quarter worth $30,107,000. Affinity Asset Advisors LLC boosted its position in shares of Avalo Therapeutics by 27.6% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company’s stock worth $20,019,000 after purchasing an additional 289,786 shares in the last quarter. Seven Fleet Capital Management LP boosted its position in shares of Avalo Therapeutics by 34.3% during the 2nd quarter. Seven Fleet Capital Management LP now owns 770,765 shares of the company’s stock worth $14,244,000 after purchasing an additional 196,882 shares in the last quarter. Squarepoint Ops LLC grew its stake in shares of Avalo Therapeutics by 624.9% during the 2nd quarter. Squarepoint Ops LLC now owns 589,245 shares of the company’s stock worth $10,889,000 after purchasing an additional 507,960 shares during the period. Finally, Bank of America Corp DE grew its stake in shares of Avalo Therapeutics by 3.5% during the 1st quarter. Bank of America Corp DE now owns 643,000 shares of the company’s stock worth $9,600,000 after purchasing an additional 21,650 shares during the period. Institutional investors and hedge funds own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research strategy centers on treatments intended to address conditions in which abnormal immune system activity contributes to disease progression.

Avalo’s lead product candidate is AVTX-009, an investigational fully human monoclonal antibody designed to inhibit interleukin-1 beta (IL-1β), a signaling protein involved in inflammation.